Circulating Tumor Cell Enumeration and Characterization in Metastatic Castration-Resistant Prostate Cancer Patients Treated with Cabazitaxel

Kruijff, Ingeborg E. de; Sieuwerts, Anieta M.; Onstenk, Wendy; Kraan, Jaco; Smid, Marcel; Van, Mai; Vlugt-Daane, Michelle van der; Hoop, Esther Oomen–de; Mathijssen, Ron H.J.; Lolkema, Martijn P.; Wit, Ronald de; Hamberg, Paul; Meulenbeld, Hielke J.; Beeker, Aart; Creemers, Geert-Jan; Martens, John W.M.; Sleijfer, Stefan

doi:10.3390/cancers11081212

Cited by 21 publications

(11 citation statements)

References 46 publications

(55 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Even in the dire situation of CRPC, patients who failed docetaxel, enzalutamide or abiraterone and switched to cabazitaxel, the information gained on survival was substantial (median OS 6.9 and 22.3 months in ≥5CTCs and <5CTCs//7.5 mL, respectively) [ 13 ] (LE 2b). A similar correlation was observed for progression free survival (PFS) in CRPC patients switching to abiraterone (LE 2b), enzalutamide (LE 4) [ 18 , 36 ] or cabazitaxel [ 17 ] (LE 4). Others addressed the dynamics of CTC counts under treatment, confirming that increasing numbers were predictive of decreased survival [ 27 , 36 , 46 ] (LE 4), while declining numbers predicted good survival [ 28 , 46 ] (LE 4).…”

Section: Resultssupporting

confidence: 55%

“…After applying all the selection criteria, the final sample comprised 46 articles on metastatic PC [ 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 , 51 , 52 , 53 , 54 ] ( Supplementary Table S1 ) and 15 articles on localized PC [ 55 , 56 , 57 , 58 , 59 , 60 …”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

A Systematic Review of Circulating Tumor Cells Clinical Application in Prostate Cancer Diagnosis

Enikeev

Morozov

Babaevskaya

et al. 2022

Cancers

View full text Add to dashboard Cite

The purpose of the review is to summarize the recent data on circulating tumor cells (CTC) use in clinical practice. We performed a systematic literature search using two databases (Medline and Scopus) over the past five years and the following terms: (CTC OR “circulating tumor cells” OR “liquid biopsy”) AND prostate. The primary outcome was CTC predictive value for prostate cancer (PC) progression and survival. The secondary outcomes were the CTC predictive value for therapy response and the results of CTC detection depending on the assessment method. In metastatic PC, the CTC count showed itself to be a prognostic marker in terms of clinically important features, namely survival rates and response to treatment. CTC concentration was significantly associated with the overall survival and progression-free survival rates. A strong association between the overall survival or progression-free survival rate and CTC concentration could be observed. Variant-7 androgen receptors-positive (AR-V7-positive) patients showed a poor response to androgen receptor signaling (ARS) inhibitors, but this did not compromise their response to taxanes. In localized PC, only positive Cluster of Differentiantion 82 protein (CD82+) correlated with a higher survival rate. CTC count and AR-V7 expression showed itself to be a valuable biomarker for survival in metastatic PC and response to ARS-inhibitors. CTC diagnostic performance for localized PC or for screening and early detection is not high enough to show additional value over the other biomarkers.

show abstract

Section: Resultssupporting

confidence: 55%

Section: Resultsmentioning

confidence: 99%

A Systematic Review of Circulating Tumor Cells Clinical Application in Prostate Cancer Diagnosis

Enikeev

Morozov

Babaevskaya

et al. 2022

Cancers

View full text Add to dashboard Cite

show abstract

“…Patients with baseline CTC counts > 5 cells/7.5 ml showed decreased OS and lower adherence to radium-223 therapy in a study [24]. Patients with < 5 CTCs prior to start of cabazitaxel therapy was prognostic indicator of better PFS and OS as compared to patients with ≥ 5 CTCs at baseline (both p < 0.001) [25]. Low CTC count was associated with longer OS than high CTC count [16.6 months (95% CI 11.7, 20.9) and 8.9 months (95% CI 6.3, 11.2)] on treatment with abiraterone or enzalutamide [26].…”

Section: Number Of Circulating Tumor Cell Count (Ctc)mentioning

confidence: 99%

Clinical implication of prognostic and predictive biomarkers for castration-resistant prostate cancer: a systematic review

et al. 2020

View full text Add to dashboard Cite

Background: Diagnosis of metastatic castrate resistant prostate cancer (mCRPC) with current biomarkers is difficult and often results in unnecessary invasive procedures as well as over-diagnosis and over-treatment. There are a number of prognostic biomarkers for CRPC, but there are no validated predictive biomarkers to guide in clinical decision-making. Specific biomarkers are needed that enable to understand the natural history and complex biology of this heterogeneous malignancy, identify early response to treatment outcomes and to identify the population of men most likely to benefit from the treatment. In this systematic review, we discuss the existing literature for the role of biomarkers in CRPC and how they aid in the prognosis, treatment selection and survival outcomes. Methods: We performed a literature search on PubMed and EMBASE databases from January 2015 through February 2020 in accordance to Preferred Reporting Items for Systematic Review and Meta-Analysis guidelines. Articles were assessed to identify relevant observational studies and randomized controlled trials regarding biomarkers which aid in identifying progression to mCRPC as well as predictive biomarkers which help in treatment selection. Results: We identified 3640 number of hits of which 58 articles were found to be relevant. Here we addressed biomarkers in the context of prognosis, prediction and patient selection of therapy. These biomarkers were found to be effective as prognostic or predictive factors under variety of conditions. The higher levels for all these biomarkers were associated with shorter median OS and sometimes PFS. Lower amounts of biomarkers in serum or urine were associated with prolonged survival outcomes, longer time to CRPC development or CRPC progression and longer median follow-up irrespective of any therapy. Conclusion: We observed that the biomarkers included in our study predicted clinically relevant survival outcomes and treatment exposure. Though the current biomarkers are prognostic when measured prior to initiating treatment, not all are validated as predictive markers in post treatment setting. A greater understanding of biomarkers in CRPC is need of the hour for development of more personalized approach to maximize benefit and minimize harm in men with CRPC.

show abstract

“…erefore, the Prostate Cancer Clinical Trials Working Group 3 recommends serial biologic profiling using tumor samples from biopsies or blood-based assays of circulating tumor cells (CTCs) or cell-free nucleic acids [15]. CTC enumeration and changes in CTC counts during treatment were identified as independent surrogate markers for survival outcomes of patients with mCRPC [29,30]. However, these biologic assessments are not available in general clinical practice in Japan.…”

Section: Discussionmentioning

confidence: 99%

Sequential Docetaxel in ≥7 Cycles Followed by Cabazitaxel Improves Oncological Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer

Kato

Takai

Iinuma

et al. 2021

The Scientific World Journal

View full text Add to dashboard Cite

Background. Docetaxel (DOC) was the first regimen that increased the survival and became the standard-of-care in patients with metastatic castration-resistant prostate cancer (mCRPC). However, it is unclear whether switching to second-line chemotherapy or optimal sequencing of cabazitaxel (CBZ) ensures better clinical outcomes. We aimed to evaluate the efficacy of sequential therapy with DOC and CBZ and the effect of the number of prior DOC cycles on oncological outcomes in patients with mCRPC. Methods. We retrospectively included 46 mCRPC patients who received DOC followed by CBZ at quaternary hospitals in Japan between February 2015 and March 2019. Participants received intravenous DOC (40–75 mg/m2) every 3–4 weeks; CBZ (15–25 mg/m2) was administered every 3–4 weeks. Androgen-deprivation therapy and prednisolone 5 mg (twice daily) were administered throughout both regimens. The primary endpoints were overall (OS) and progression-free survival (PFS). The secondary endpoints were the rates of ≥30% and ≥50% reduction in prostate-specific antigen (PSA) levels at chemotherapy initiation. Results. Participants were divided into two groups according to DOC cycles (Groups A and B: ≤6 and ≥7 DOC cycles, respectively). The rates of ≥30% and ≥50% reduction in PSA levels were higher in Group B than in Group A, but there were no significant differences in both groups. Median OS in Groups A and B was 12.7 and 71.0 months, respectively P < 0.001 ; median PFS in Groups A and B was 3 and 12 months, respectively P < 0.001 . Conclusions. Administration of ≥7 cycles of DOC followed by CBZ may improve oncological outcomes in patients with mCRPC.

show abstract

Circulating Tumor Cell Enumeration and Characterization in Metastatic Castration-Resistant Prostate Cancer Patients Treated with Cabazitaxel

Cited by 21 publications

References 46 publications

A Systematic Review of Circulating Tumor Cells Clinical Application in Prostate Cancer Diagnosis

A Systematic Review of Circulating Tumor Cells Clinical Application in Prostate Cancer Diagnosis

Clinical implication of prognostic and predictive biomarkers for castration-resistant prostate cancer: a systematic review

Sequential Docetaxel in ≥7 Cycles Followed by Cabazitaxel Improves Oncological Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer

Contact Info

Product

Resources

About